Las Vegas, NV -- (SBWIRE) -- 09/25/2013 -- Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks. Let’s have a brief look at: FreeSeas Inc.(NASDAQ:FREE), Kandi Technologies Group Inc(NASDAQ:KNDI), Cell Therapeutics Inc(NASDAQ:CTIC), Acura Pharmaceuticals, Inc.(NASDAQ:ACUR)
FreeSeas Inc.(NASDAQ:FREE) ended higher +7.51% and complete the day at $0.500. The total number of shares changed hands during the day was 7.91 million. After opening at $0.46, the stock hit as high as $0.50. However, it traded between $0.17and $5.80 over the last twelve months. FreeSeas Inc., through its subsidiaries, provides drybulk shipping services. Its vessels carry various drybulk commodities, including iron ore, grain, and coal, as well as bauxite, phosphate, fertilizers, steel products, cement, sugar, and rice.
For How Long FREE will Fight for Profitability? Read This Trend Analysis report
Kandi Technologies Group Inc(NASDAQ:KNDI) closed yesterday at $8.34, a+18.47% increase. Around 7.78 million shares were traded, beating an-average trading volume of 1.41 million shares. The company is now valued at around $308.32 million. Kandi Technologies Group, Inc., through its subsidiaries, engages in the design, development, manufacture, and commercialization of various vehicles.
For How Long KNDI’s Gloss will Attract Investors? Find out via this report
Cell Therapeutics Inc(NASDAQ:CTIC) moved +3.56 percent higher at $1.60 and traded between $1.58 and $1.77 after opening the day at $1.61. Its performance over the last five days remained +22.14%, which stands at +39.13% for a month. Going back further than one month, 1-year performance after recent close was +23.08%. Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer.
Will CTIC Continue To Move Higher? Find Out Here
Acura Pharmaceuticals, Inc.(NASDAQ:ACUR)’s shares rose, gaining +27.52 percent to close at $1.90. The stock is up around -14.41% this year and +3.83% for the last 12 months. Around 7.30 million shares changed hands yesterday, higher from an-average trading volume of 260,436.00 shares. Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies.
Why Should Investors Buy ACUR After The Recent Gain? Just Go Here and Find Out
Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks.
PLEASE NOTE WELL: The employees of ValueStockPick.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site, Press releases or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Please Read Our Full Disclaimer at http://www.valuestockpick.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)